John Celebi - 15 Feb 2023 Form 4/A - Amendment Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role: President and CEO, Director
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol: SNSE
Transactions as of: 15 Feb 2023
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 29 Mar 2023, 17:16:07 UTC
Date Of Original Report: 17 Feb 2023
Previous filing: 17 Feb 2022
Next filing: 13 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SNSE	Common Stock	Award	$0	+51,893	+89%	$0.000000	110,003	15 Feb 2023	Direct	F1, F2, F3
transaction	SNSE	Common Stock	Award	$0	+21,300	+19%	$0.000000	131,303	15 Feb 2023	Direct	F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNSE	Stock Option (Right to Buy)	Award	$0	+90,000		$0.000000	90,000	15 Feb 2023	Common Stock	90,000	$1.43	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This amendment is being filed solely to correct the number of shares beneficially owned. Due to administrative error the original filing did not include shares purchased under the Issuer's Employee Stock Purchase Plan ("ESPP").
F2	These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested.
F3	Share balance includes stock purchased under the ESPP not previously reported.
F4	These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date.
F5	The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.